Advisory Services Network’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-409
| Closed | -$23.1K | – | 2466 |
|
|
2026
Q1 | $23.1K | Buy |
+409
| New | +$23.8K | ﹤0.01% | 3116 |
|
|
2025
Q4 | – | Sell |
-286
| Closed | -$15.5K | – | 2102 |
|
|
2025
Q3 | $15.5K | Buy |
+286
| New | +$16.4K | ﹤0.01% | 3076 |
|
|
2024
Q1 | – | Sell |
-327
| Closed | -$31.5K | – | 1724 |
|
|
2023
Q4 | $31.5K | Buy |
+327
| New | +$28.9K | ﹤0.01% | 2272 |
|
|
2023
Q2 | – | Sell |
-429
| Closed | -$41.7K | – | 1711 |
|
|
2023
Q1 | $41.7K | Buy |
429
+102
| +31% | +$10.6K | ﹤0.01% | 2113 |
|
|
2022
Q4 | $33.8K | Buy |
+327
| New | +$30.7K | ﹤0.01% | 2179 |
|
|
2021
Q3 | – | Sell |
-501
| Closed | -$41K | – | 1618 |
|
|
2021
Q2 | $41K | Buy |
+501
| New | +$39.7K | ﹤0.01% | 2104 |
|
|
2021
Q1 | – | Sell |
-534
| Closed | -$47K | – | 1478 |
|
|
2020
Q4 | $47K | Buy |
534
+173
| +48% | +$13.7K | ﹤0.01% | 1708 |
|
|
2020
Q3 | $28K | Buy |
+361
| New | +$36.5K | ﹤0.01% | 1895 |
|
|
2020
Q2 | – | Sell |
-252
| Closed | -$22K | – | 1234 |
|
|
2020
Q1 | $22K | Buy |
252
+26
| +12% | +$2.24K | ﹤0.01% | 1803 |
|
|
2019
Q4 | $19K | Buy |
226
+4
| +2% | +$302 | ﹤0.01% | 2031 |
|
|
2019
Q3 | $18K | Hold |
222
| – | – | ﹤0.01% | 1870 |
|
|
2019
Q2 | $18K | Buy |
222
+15
| +7% | +$1.28K | ﹤0.01% | 1868 |
|
|
2019
Q1 | $19K | Sell |
207
-546
| -73% | -$50.6K | ﹤0.01% | 1632 |
|
|
2018
Q4 | $64K | Buy |
753
+86
| +13% | +$8.18K | 0.01% | 1048 |
|
|
2018
Q3 | $65K | Buy |
667
+42
| +7% | +$4.19K | ﹤0.01% | 1127 |
|
|
2018
Q2 | $64K | Buy |
625
+526
| +531% | +$46.1K | ﹤0.01% | 1122 |
|
|
2018
Q1 | $8K | Hold |
99
| – | – | ﹤0.01% | 1938 |
|
|
2017
Q4 | $9K | Hold |
99
| – | – | ﹤0.01% | 1864 |
|
|
2017
Q3 | $9K | Hold |
99
| – | – | ﹤0.01% | 1643 |
|
|
2017
Q2 | $9K | Hold |
99
| – | – | ﹤0.01% | 1581 |
|
|
2017
Q1 | $9K | Buy |
+99
| New | +$8.81K | ﹤0.01% | 1497 |
|
|
2016
Q3 | $23K | Sell |
247
-285
| -54% | -$26.8K | ﹤0.01% | 1080 |
|
|
2016
Q2 | $41K | Buy |
532
+483
| +986% | +$41.1K | 0.01% | 844 |
|
|
2016
Q1 | $4K | Hold |
49
| – | – | ﹤0.01% | 1307 |
|
|
2015
Q4 | $5K | Sell |
49
-908
| -95% | -$94.8K | ﹤0.01% | 1112 |
|
|
2015
Q3 | $101K | Buy |
957
+137
| +17% | +$18.3K | 0.03% | 398 |
|
|
2015
Q2 | $112K | Sell |
820
-91
| -10% | -$11.3K | 0.03% | 358 |
|
|
2015
Q1 | $108K | Buy |
911
+862
| +1,759% | +$91.3K | 0.03% | 367 |
|
|
2014
Q4 | $5K | Buy |
+49
| New | +$4.08K | ﹤0.01% | 887 |
|
Other funds holding BMRN
VPC
Advisory Services Network's BMRN Position: Q2 2026 in Review
Advisory Services Network sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 409 shares — an estimated $23.1K sold.
Advisory Services Network first reported a position in BMRN in Q4 2014 and held it in 29 quarters. The position peaked at $112K in Q2 2015. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Advisory Services Network reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Advisory Services Network sold 409 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $23.1K.
- Advisory Services Network first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 29 quarters.
- Advisory Services Network's BioMarin Pharmaceuticals position peaked at $112K in Q2 2015.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.